GlassScriptPhysician profile
Jonathan F Moravek
NPI 1578672523
$18,503.42
in general payments reported to CMS, 2019-2025
83 companies · $4,033 in 2025
The $4,033 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,626 · 2020: $452 · 2021: $1,472 · 2022: $2,239 · 2023: $3,463 · 2024: $4,217 · 2025: $4,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,373.76 |
| Education | $339.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,179.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,140.01 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,077.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $896.19 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Biogen, INC. | $780.64 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
| Lundbeck LLC | $772.22 | 2019-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $716.72 | 2022-2025 | Ingrezza |
| Amgen INC. | $711.25 | 2019-2025 | Aimovig, Uplizna |
| Lilly USA, LLC | $667.88 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Pfizer INC. | $556.61 | 2019-2025 | |
| Mdd US Operations, LLC | $466.85 | 2021-2025 | Gocovri, Gocovri |
| Supernus Pharmaceuticals, INC. | $462.03 | 2019-2022 | |
| Argenx US, INC. | $436.59 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $404.03 | 2019-2025 | Mavenclad |
| Csl Behring | $392.63 | 2019-2025 | Hizentra |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Moravek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.